ReviewFrontiers in medicine2025
Application and research progress of tranexamic acid in the perioperative period of posterior lumbar interbody fusion.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A comparative study of O-arm navigation-assisted OLIF 360 versus traditional OLIF combined with Mazor Renaissance robot-assisted posterior fixation for single-level lumbar spondylolisthesis: clinical and radiographic outcomes.Journal of orthopaedic surgery and research · 2026Article
- The impact of preoperative anticoagulant administration on postoperative coagulation function and blood loss following posterior lumbar interbody fusion: a case-control study.Frontiers in medicine · 2026Article
- The influence of tranexamic acid on intraoperative blood transfusion in short-segment PLIF and analysis of influencing factors of the transfusion: a retrospective case study.Frontiers in pharmacology · 2026Article
- Safety and effectiveness of intravenous tranexamic acid for posterior lumbar interbody fusion in patients on preoperative anticoagulants: a retrospective case-control study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior lumbar interbody fusion requires stripping the multifidus muscle, destroying a large amount of cancellous bone and damaging the posterior spinal venous plexus. Typically, surgical trauma is extensive, the surgical duration is long, and the degree of bleeding is substantial. Excessive blood loss can compromise a patient's hemodynamic stability, elevate surgical risks, and cause damage to vital organs, potentially becoming life-threatening in severe cases. Tranexamic acid (TXA) is a lysine derivative that can inhibit fibrinolysis, reduce D-dimer production, and reduce inflammation. In this review, we discuss the application of and research progress on TXA regarding its mechanism of action, mode of administration, timing, dose, safety, and economic benefits. The primary purpose of this review is to provide an essential reference for the administration of TXA during posterior lumbar interbody fusion surgery as well as a reference for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.